ImmuneResearch Phase

Thymulin

Subcutaneous injection, Intranasal

Overview

A zinc-containing nonapeptide (facteur thymique serique) produced exclusively by thymic epithelial cells. Thymulin requires zinc for biological activity and promotes T-lymphocyte differentiation, maturation, and function.

Mechanism of Action

Circulating thymulin levels decline progressively with age in parallel with thymic involution, and zinc deficiency independently impairs thymulin activity, linking nutritional status to immune competence..

Research Summary & Key Findings

Serum thymulin levels correlate with thymic function and decline markedly after age 60. Zinc supplementation partially restores thymulin activity in elderly and zinc-deficient populations (Prasad et al., Am J Clin Nutr, 1993). Intranasal thymulin reduced lung inflammation in animal models of asthma and ARDS. Research suggests potential for immune reconstitution in aging populations through combined thymulin and zinc therapy.

Clinical Status

Research Phase

Thymulin is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Subcutaneous injectionIntranasal

Related Peptides in Immune

Find a Provider

Find a verified provider who offers Thymulin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Thymulin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.